EXAS vs. GH

Last updated Jun 4, 2026

EXAS (Exact Sciences Corporation) and GH (Guardant Health, Inc.) are both stocks. Both operate in the Diagnostics & Research industry within the Healthcare sector. At a 0.47 correlation, their price movements are largely independent.

Performance

EXAS vs. GH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exact Sciences Corporation (EXAS) and Guardant Health, Inc. (GH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

EXAS

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

GH

• 1D: -2.41%
• 1M: 39.33%
• YTD: 24.37%
• 6M: 19.88%
• 1Y: 177.42%
• 3Y*: 57.70%
• 5Y*: 1.54%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

EXAS vs. GH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
EXAS Exact Sciences Corporation	3.30%	80.74%	-24.05%	49.42%	-36.39%	-41.26%	43.26%	46.56%	-12.91%
GH Guardant Health, Inc.	24.37%	234.34%	12.94%	-0.55%	-72.81%	-22.39%	64.93%	107.87%	16.74%

Correlation

The correlation between EXAS and GH is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.10
Correlation (3Y) Calculated over the trailing 3-year period	0.30
Correlation (5Y) Calculated over the trailing 5-year period	0.46
Correlation (All Time) Calculated using the full available price history since Oct 5, 2018	0.47

Over the past year, the correlation between EXAS and GH has dropped to 0.10 - well below their long-term average of 0.47, suggesting their price drivers have been diverging.

Fundamentals

Market Cap EXAS : $19.91B GH : $16.68B
EPS EXAS : -$1.10 GH : -$3.40
PS Ratio EXAS : 6.12 GH : 14.97
Total Revenue (TTM) EXAS : $3.25B GH : $1.08B
Gross Profit (TTM) EXAS : $2.26B GH : $701.01M
EBITDA (TTM) EXAS : $42.61M GH : -$411.42M

Return for Risk

EXAS vs. GH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GH

GH Risk / Return Rank: 93
GH Sharpe Ratio Rank: 94
GH Sortino Ratio Rank: 93
GH Omega Ratio Rank: 92
GH Calmar Ratio Rank: 92
GH Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXAS vs. GH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exact Sciences Corporation (EXAS) and Guardant Health, Inc. (GH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	EXAS	GH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	3.09	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.02	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.29	—

Drawdowns

Drawdown Indicators

	EXAS	GH	Difference
Max Drawdown Largest peak-to-trough decline	—	-91.03%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-32.98%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-59.79%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-87.84%	—
Current Drawdown Current decline from peak	—	-29.07%	—
Average Drawdown Average peak-to-trough decline	—	-51.68%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	13.26%	—

Volatility

Volatility by Period

	EXAS	GH	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	18.85%	—
Volatility (6M) Calculated over the trailing 6-month period	—	37.92%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	58.38%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	67.65%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	68.13%	—

Dividends

EXAS vs. GH - Dividend Comparison

Neither EXAS nor GH has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

EXAS vs. GH - Profitability Comparison

The chart below illustrates the profitability comparison between Exact Sciences Corporation and Guardant Health, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

EXAS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a gross profit of 615.83M and revenue of 878.38M. Therefore, the gross margin over that period was 70.1%.

GH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported a gross profit of 196.75M and revenue of 301.67M. Therefore, the gross margin over that period was 65.2%.

EXAS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported an operating income of -76.68M and revenue of 878.38M, resulting in an operating margin of -8.7%.

GH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported an operating income of -121.35M and revenue of 301.67M, resulting in an operating margin of -40.2%.

EXAS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Exact Sciences Corporation reported a net income of -85.96M and revenue of 878.38M, resulting in a net margin of -9.8%.

GH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Guardant Health, Inc. reported a net income of -112.08M and revenue of 301.67M, resulting in a net margin of -37.2%.

Frequently Asked Questions

Can I hold both EXAS and GH in my portfolio?

EXAS and GH have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.